Circulating tumor cells and circulating tumor DNA: What surgical oncologists need to know?

Luc Cabel(Université de Versailles Saint-Quentin-en-Yvelines), François‐Clément Bidard(Inserm), Jean‐Yves Pierga(Université Paris Cité), Charlotte Proudhon(Inserm), Ivan Bièche(Centre National de la Recherche Scientifique), Guillaume Beinse(Université Paris Sciences et Lettres), Pascale Mariani(Université Paris Sciences et Lettres), Dimitri Tzanis(Université Paris Cité)
European Journal of Surgical Oncology
January 29, 2017
10.1016/j.ejso.2017.01.010
Cited by 45

Related Papers

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
|New England Journal of Medicine|2016|2k
Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial
|The Lancet Oncology|2021|812
Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial
|Journal of Clinical Oncology|2022|676